Earnings Call Transcripts
Access detailed transcripts and key takeaways from company earnings calls
All Earnings Calls
BioStem Technologies Q4 2025 Earnings Call - BioTissue Acquisition Repositions Firm Toward Hospital Revenue to Offset Medicare Headwinds
BioStem used the Q4 call to announce a sharp strategic pivot. Management closed the BioTissue surgical and wound assets on January 21, 2026, and is reallocating sales and commercial resources toward h...
- BioStem reported Q4 2025 revenue of $10.1 million, nearly flat vs the prior period ($10.5M) but down from $22.7 million in Q4 2024.
- Q4 gross profit was $9.8 million, implying a 97% gross margin, up from 88% in the prior period and 84% in Q4 2024, driven by product mix favoring items without licensing fees.
- Operating expenses jumped to $17.3 million in Q4, primarily due to an $8.8 million allowance for potentially uncollectible receivables from distributor Venture Medical, tied to CMS payment delays and denials.
- +15 more takeaways
BioCardia Q4 2025 Earnings Call - CardiAMP echo data points to potential approval focused on high NT-proBNP subgroup
BioCardia leaned hard on new echocardiography findings from its phase III CardiAMP HF trial, arguing the therapy suppresses pathological ventricular remodeling most convincingly in patients with eleva...
- CardiAMP HF echocardiography core-lab data show left ventricular volume reductions trending in the full cohort with p-values of 0.06 (end-diastolic) and 0.09 (end-systolic), just above conventional significance thresholds.
- Pre-specified subgroup with elevated NT-proBNP produced statistically significant echo benefits: reductions >20 mL/m2 and >15 mL/m2 with p-values of 0.02 and 0.01 respectively.
- Three independent clinical trials now have final or complete data showing consistent directionality: reduced fatal and non-fatal MACE and improved quality of life, strongest in the NT-proBNP high subgroup.
- +13 more takeaways
REPAY Q4 2025 Earnings Call - Exited 2025 with normalized growth, guiding to double-digit 2026 and ~40% Adj. EBITDA
REPAY closed 2025 with a clear pivot back to normalized growth and strong profitability. Q4 revenue was $78.6 million with gross profit of $58.3 million, translating to 10% normalized revenue growth a...
- Q4 revenue was $78.6 million, Q4 gross profit was $58.3 million, with normalized revenue growth of 10% and normalized gross profit growth of 9% year over year after excluding 2024 political media contributions.
- Adjusted EBITDA for Q4 was $32.4 million, implying a 41% Adjusted EBITDA margin; management expects roughly 40% Adjusted EBITDA margins for full-year 2026.
- 2026 guidance: revenue $340 million to $346 million, representing 10% to 12% reported growth and about 7% to 9% normalized growth excluding political media contributions.
- +12 more takeaways
Perma-Fix Environmental Services Q4 2025 Earnings Call - Hanford ramp and permit expansion set stage for a Q2 revenue inflection
Perma-Fix used 2025 to bulk up capacity and regulatory footing, centering its 2026 outlook on the Hanford cleanup ramp and expanded processing at Perma-Fix Northwest. Management highlights a renewed p...
- Revenue and profit snapshot: FY2025 revenue was $61.7 million, up 4.3% from 2024; Q4 revenue was $15.7 million, up 6.9% year over year. FY net loss narrowed to $13.8 million from $20.0 million in 2024.
- Treatment segment strength: Treatment revenue grew materially, up 29% year over year per management commentary, driven by higher volumes and improved plant throughput. Treatment backlog was cited as up 51% to about $1.9 million by the CEO, while the CFO reported a waste treatment backlog of $11.9 million at year end, a discrepancy investors should clarify.
- Permitting milestone at Northwest: Perma-Fix Northwest renewed its permit, expanding permitted liquid mixed waste processing to roughly 1.2 million gallons annually and authorizing macroencapsulation up to 175,000 tons, tripling prior liquid capacity and enabling faster permit mods going forward.
- +13 more takeaways
Leatt Corporation Q4 2025 Earnings Call - International Demand Drives 41% Full-Year Revenue Growth and Margin Expansion
Leatt closed 2025 with a clear breakout year, reporting $61.91 million in revenue, up 41% year over year, powered by a 47% jump in international sales and stronger direct-to-consumer traction. Margins...
- Full-year 2025 revenue was $61.91 million, a 41% increase versus 2024.
- Fourth quarter 2025 revenue was $16.0 million, up 43% year over year.
- International revenues for 2025 were $44.64 million, up 47% year over year and the primary growth engine.
- +12 more takeaways
Smithfield Foods Fourth Quarter 2025 Earnings Call - Record profits, tight leverage, big Sioux Falls build and Nathan's deal set to accelerate growth
Smithfield closed 2025 with an operational hat trick, delivering record adjusted operating profit of $1.3 billion, expanded margins, and roughly $1 billion of adjusted net income while sitting on a fo...
- Record 2025 financials: adjusted operating profit rose 30% to $1.3 billion, with adjusted operating margin expanding to 8.6% from 7.2% in 2024.
- Adjusted net income from continuing operations was roughly $1.0 billion for 2025, and adjusted diluted EPS was $2.55, up 36% year over year.
- Fourth quarter highlights: adjusted operating profit of $402 million and adjusted net income of $329 million, the company’s second highest quarterly net income on record.
- +11 more takeaways
LENZ Therapeutics Q4 2025 Earnings Call - VIZZ proves effective in early launch, but category build will take time
LENZ walked investors through five months of the VIZZ (LNZ100) launch with a clear message, confident metrics, and a healthy war chest. The product is delivering fast, observable benefit in the clinic...
- Product efficacy confirmed in real world: VIZZ (LNZ100) produces rapid, noticeable improvement in near vision for many patients, often within about 30 minutes and lasting up to ~10 hours.
- Early commercial traction: since launch through end of the quarter LENZ sold over 45,000 monthly packs and recorded more than 20,000 paid and filled prescriptions in the first quarter of sales.
- Broad prescriber footprint: more than 10,000 eye care professionals have prescribed VIZZ, exceeding comparable early-stage launches like Miebo and Vuity at the same point.
- +12 more takeaways
Core & Main Q4 and Full Year 2025 Earnings Call - Gaining Share and Margins with Meters, Treatment and Private Label as Residential Stalls
Core & Main closed fiscal 2025 with durable cash flow and share gains even as end markets were uneven. Net sales were $7.65 billion, Adjusted EBITDA $931 million, adjusted diluted EPS $2.97, and opera...
- Core & Main reported FY2025 net sales of $7.65 billion, Adjusted EBITDA of $931 million, adjusted diluted EPS of $2.97, and operating cash flow of $650 million.
- The company delivered its 16th consecutive year of sales growth and estimates roughly 20% U.S. market share in a ~$44 billion addressable market (U.S. and Canada).
- End-market mix: municipal 44% of sales, non-residential ~38%, residential lot development ~18%. Municipal volumes were up low- to mid-single digits, non-residential roughly flat, and residential down low double digits in FY2025.
- +14 more takeaways
Achieve Life Sciences Q4 2025 Earnings Call - NDA Accepted, PDUFA Set for June 20; Aims for 1H 2027 U.S. Launch with Onshore Manufacturing
Achieve Life Sciences spent 2025 moving cytisinicline from a development story to a near-commercial company. The company confirmed NDA acceptance and a PDUFA date set for June 20, while securing a Com...
- NDA for cytisinicline was submitted and accepted, management confirms the PDUFA date remains set for June 20.
- Achieve received a Commissioner’s National Priority Voucher for the vaping cessation indication, which should shorten FDA review from a typical 10-12 months to an accelerated 1-2 month timeline for that pathway.
- Company plans a U.S. commercial launch in the first half of 2027, contingent on securing product supply and completing remaining launch-ready operations.
- +12 more takeaways
Fennec Pharmaceuticals Q4 and Full Year 2025 Earnings Call - Record Sales, Commercial Ramp and Patent Settlement Extends Exclusivity to 2033
Fennec closed 2025 with clear commercial momentum and a cleaner balance sheet. Net product sales jumped to $44.6 million for the year, a roughly 50% increase versus 2024, and Q4 sales came in at $13.8...
- Net product sales were $13.8 million in Q4 2025, up ~75% from $7.9 million in Q4 2024; full year 2025 net product sales were $44.6 million versus $29.6 million in 2024, about a 50% increase.
- Fennec attributes growth to quarter-over-quarter expansion in active patients, new and existing account uptake, and stronger conversion and adherence driven by commercial execution.
- The Fennec HEARS patient support program hit record enrollments, prescribed and infused vials, active patients, and improved conversion rates, rising from roughly 50% in Q1 to ~70% in Q4.
- +12 more takeaways